Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 7:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 497 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Elevated Cardiovascular Risk Clear all
Completed No phase listed Observational

Risk-score Based ICU Triage

NCT03390270
View directory record Official record
Conditions
Non-ST Elevation Myocardial Infarction (nSTEMI)
Interventions
Admission with NSTEMI
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Oct 5, 2026, 7:41 AM EDT
Not listed No phase listed Observational

Heart Failure Event Advance Detection Trial

NCT04223271
View directory record Official record
Conditions
Congestive Heart Failure, Heart Failure, Decompensated Heart Failure
Interventions
Indicor
Diagnostic Test
Lead sponsor
Vixiar Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Oct 5, 2026, 7:41 AM EDT
Completed No phase listed Observational

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

NCT00377949
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma, Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 75 Years
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
25
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 5, 2026, 7:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Serum Markers for Cardiovascular Risk in Obese Youth and Impact of Lifestyle and Medication Intervention

NCT00139477
View directory record Official record
Conditions
Obesity
Interventions
Metformin, Dietary modification with caloric restriction, Establishment of exercise protocol
Drug · Behavioral
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
7 Years to 18 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 5, 2026, 7:41 AM EDT
Completed Phase 1 Interventional

Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma

NCT01330173
View directory record Official record
Conditions
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Vismodegib, Pharmacological Study, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 5, 2026, 7:41 AM EDT
Completed Not applicable Interventional Results available

REVEAL AF: Incidence of AF in High Risk Patients

NCT01727297
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
REVEAL Implantable Cardiac Monitor
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
43
States / cities
Glendale, Arizona • Fresno, California • Palm Springs, California + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Oct 5, 2026, 7:41 AM EDT
Completed Phase 1 Interventional

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

NCT00477035
View directory record Official record
Conditions
Leukemia, Multiple Myeloma
Interventions
CIK cells, etoposide, bcnu, cyclophosphamide, gemcitabine, vinorelbine, melphalan
Drug
Lead sponsor
Sally Arai
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 5, 2026, 7:41 AM EDT
Completed Not applicable Interventional

Randomized Trial to Evaluate the Effectiveness of Nurse Case Management

NCT00295256
View directory record Official record
Conditions
Type 2 Diabetes, Gestational Diabetes, Hypertension, Preterm Delivery
Interventions
nurse case manager
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
15 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 5, 2026, 7:41 AM EDT
Completed Phase 1 Interventional

Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study

NCT02697383
View directory record Official record
Conditions
Multiple Myeloma, High Risk Smoldering Multiple Myeloma
Interventions
Ixazomib (MLN9708), Dexamethasone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Oct 5, 2026, 7:41 AM EDT
Recruiting Phase 2 Interventional

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

NCT05208307
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Belantamab Mafodotin, Dexamethasone, Pomalidomide
Biological · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 5, 2026, 7:41 AM EDT
Recruiting Phase 2 Interventional

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

NCT07783802
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
Interventions
Clazakizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
30
States / cities
Huntsville, Alabama • Tucson, Arizona • Glendora, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 5, 2026, 7:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

High Risk Multiple Gestation Study

NCT02278874
View directory record Official record
Conditions
Trisomy 13, Trisomy 18, Trisomy 21, Sex Chromosome Abnormalities
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
4
States / cities
Boston, Massachusetts • Glen Cove, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 5, 2026, 7:41 AM EDT
Completed Phase 4 Interventional Results available

Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up

NCT01863134
View directory record Official record
Conditions
Non ST Elevation Myocardial Infarction
Interventions
Eptifibatide, Placebo
Drug
Lead sponsor
Medical University of Silesia
Other
Eligibility
21 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 5, 2026, 7:41 AM EDT
Completed Not applicable Interventional

Improving Physical Activity Through a mHealth Intervention in Cardio-metabolic Risk Patients

NCT02551640
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Prediabetic State, Hypertension, Prehypertension, Obesity
Interventions
FeatForward App (on study smartphone)
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Charlestown, Massachusetts • Revere, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 5, 2026, 7:41 AM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement

NCT01531374
View directory record Official record
Conditions
Severe Aortic Stenosis
Interventions
Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
Not listed
Enrollment
2,777 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
45
States / cities
Phoenix, Arizona • Los Angeles, California • Mountain View, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 5, 2026, 7:41 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)

NCT01644175
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Placebo (for alirocumab), Alirocumab, Lipid-Modifying Therapy (LMT)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
76
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 5, 2026, 7:41 AM EDT
Recruiting Phase 4 Interventional

The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients

NCT05034432
View directory record Official record
Conditions
Arrythmia, Cardiomyopathies
Interventions
Intra-Op Prophylactic VT ablation, Conventional Management
Procedure · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 5, 2026, 7:41 AM EDT
Completed Not applicable Interventional Results available

Comparative Effectiveness of Family vs. Individually Focused Diabetes Education and Support

NCT03812614
View directory record Official record
Conditions
Diabetes Mellitus, High Blood Pressure, High Blood Sugar, Hypertension
Interventions
FAM ACT, I-DSMES
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years to 75 Years
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Detroit, Michigan • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 5, 2026, 7:41 AM EDT
Completed Phase 3 Interventional Results available

Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects

NCT02207634
View directory record Official record
Conditions
Dyslipidemia
Interventions
Evolocumab, Placebo, Background Statin Therapy
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
40 Years to 85 Years
Enrollment
1,974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
134
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 123 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 5, 2026, 7:41 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

NCT03651128
View directory record Official record
Conditions
Multiple Myeloma
Interventions
bb2121, Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Ixazomib, Lenalidomide, Carfilzomib, Elotuzumab
Biological · Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
36
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 5, 2026, 7:41 AM EDT
Completed Phase 3 Interventional Results available

GORE Embolic Protection With Reverse Flow

NCT00594100
View directory record Official record
Conditions
Carotid Artery Stenosis
Interventions
GORE Flow Reversal System (GFRS)
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Buffalo, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 27, 2013 · Synced Oct 5, 2026, 7:41 AM EDT
Recruiting Not applicable Interventional

WIREDUP: Wearable Insoles for Recurrent Diabetic Ulcer Prevention

NCT05950659
View directory record Official record
Conditions
Diabetes, Peripheral Neuropathy, Diabetic Foot, Diabetic Foot Ulcer
Interventions
Orpyx Sensory Insole System
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 5, 2026, 7:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Behavioral Economic Approaches to Increase Physical Activity Among Patients With Elevated Risk for Cardiovascular Disease

NCT03911141
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Gamification, Financial
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
1,062 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 5, 2026, 7:41 AM EDT
Completed Phase 2 Interventional Results available

An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol

NCT03060577
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis, Type2 Diabetes, Familial Hypercholesterolemia
Interventions
Inclisiran, Evolocumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
8
States / cities
Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 5, 2026, 7:41 AM EDT